Associations between B vitamins and Parkinson’s disease

Nutrients

Volumn 7, Issue 9, 2015, Pages 7197-7208

  Shen, Liang ^a  

^a SHANDONG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

B vitamins; Dietary intake; Meta analysis; Parkinson s disease

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; LEVODOPA; PYRIDOXINE; VITAMIN B GROUP; VITAMIN B COMPLEX;

ANTIOXIDANT ACTIVITY; ARTICLE; BODY MASS; CALORIC INTAKE; CLINICAL ASSESSMENT; DIETARY INTAKE; DISEASE ASSOCIATION; HUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; QUESTIONNAIRE; VITAMIN SUPPLEMENTATION; CASE CONTROL STUDY; DIET; META ANALYSIS; ODDS RATIO; PROTECTION; RISK ASSESSMENT; RISK FACTOR;

CASE-CONTROL STUDIES; DIET; FOLIC ACID; HUMANS; ODDS RATIO; PARKINSON DISEASE; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; VITAMIN B 12; VITAMIN B 6; VITAMIN B COMPLEX;

EID: 84940866150     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7095333     Document Type: Article

References (32)

1. Lees, A.J.; Hardy, J.; Revesz, T. Parkinson's disease. Lancet 2009, 373, 2055-2066. [CrossRef]
2. Connolly, B.S.; Lang, A.E. Pharmacological treatment of Parkinson disease: A review. JAMA 2014, 311, 1670-1683. [CrossRef] [PubMed]
3. De Lau, L.M.; Breteler, M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5, 525-535. [CrossRef]
4. Jenner, P. Oxidative stress in Parkinson's disease. Ann. Neurol. 2003, 53, S26-S36. [CrossRef] [PubMed]
5. Dias, V.; Junn, E.; Mouradian, M.M. The role of oxidative stress in Parkinson's disease. J. Parkinsons. Dis. 2013, 3, 461-491. [PubMed]
6. Seshadri, S.; Beiser, A.; Selhub, J.; Jacques, P.F.; Rosenberg, I.H.; D'Agostino, R.B.;Wilson, P.W.; Wolf, P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 2002, 346, 476-483. [CrossRef] [PubMed]
7. Prins, N.D.; den Heijer, T.; Hofman, A.; Koudstaal, P.J.; Jolles, J.; Clarke, R.; Breteler, M.M. Homocysteine and cognitive function in the elderly: The Rotterdam Scan Study. Neurology 2002, 59, 1375-1380. [CrossRef] [PubMed]
8. Kuhn, W.; Roebroek, R.; Blom, H.; van Oppenraaij, D.; Muller, T. Hyperhomocysteinaemia in Parkinson's disease. J. Neurol. 1998, 245, 811-812. [CrossRef] [PubMed]
9. Postuma, R.B.; Lang, A. Homocysteine and levodopa. Should parkinson disease patients receive preventative therapy? Neurology 2004, 63, 886-891. [CrossRef] [PubMed]
10. Müller, T. Role of homocysteine in the treatment of Parkinson's disease. Expert Rev. Neurother. 2008, 8, 957-967. [CrossRef] [PubMed]
11. Papazisis, K.; Kyriazis, G.; Kiosseoglou, G.; Kazis, A. Endothelial function markers in parkinsonian patients with hyperhomocysteinemia. J. Clin. Neurosci. 2005, 12, 669-672.
12. Todorovi´c, Z.; Dzolji´c, E.; Novakovi´c, I.; Mirkovi´c, D.; Stojanovi´c, R.; Nesi´c, Z.; Krajinovi´c, M.; Prostran, M.; Kosti´c, V. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J. Neurol. Sci. 2006, 248, 56-61. [CrossRef] [PubMed]
13. Rodriguez-Oroz, M.C.; Lage, P.M.; Sanchez-Mut, J.; Lamet, I.; Pagonabarraga, J.; Toledo, J.B.; García-Garcia, D.; Clavero, P.; Samaranch, L.; Irurzun, C.; et al. Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study. Mov. Disord. 2009, 24, 1437-1444. [CrossRef] [PubMed]
14. Duan, W.; Ladenheim, B.; Cutler, R.G.; Kruman, I.I.; Cadet, J.L.; Mattson, M.P. Dietary folate deficiency anded elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem. 2002, 80, 101-110. [CrossRef] [PubMed]
15. Kruman, I.I.; Culmsee, C.; Chan, S.L.; Kruman, Y.; Guo, Z.; Penix, L.; Mattson, M.P. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J. Neurosci. 2000, 20, 6920-6926. [PubMed]
16. Lipton, S.A.; Kim, W.K.; Choi, Y.B.; Kumar, S.; D'Emilia, D.M.; Rayudu, P.V.; Arnelle, D.R.; Stamler, J.S. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. USA 1997, 94, 5923-5928. [CrossRef] [PubMed]
17. Miller, J.W.; Selhub, J.; Nadeau, M.R.; Thomas, C.A.; Feldman, R.G.; Wolf, P.A. Effect of L-dopa on plasma homocysteine in PD patients: Relationship to B-vitamin status. Neurology 2003, 60, 1125-1129. [CrossRef] [PubMed]
18. Religa, D.; Czyzewski, K.; Styczynska, M.; Peplonska, B.; Lokk, J.; Chodakowska-Zebrowska, M.; Stepien, K.; Winblad, B.; Barcikowska, M. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci. Lett. 2006, 404, 56-60. [CrossRef] [PubMed]
19. Triantafyllou, N.I.; Nikolaou, C.; Boufidou, F.; Angelopoulos, E.; Rentzos, M.; Kararizou, E.; Evangelopoulos, M.E.; Vassilopoulos, D. Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: Their relationship to clinical manifestations, mood and cognition. Parkinsonism Relat. Disord. 2008, 14, 321-325. [CrossRef] [PubMed]
20. Shin, H.W.; Sohn, Y.H. Hyperhomocysteinemia in patients with Parkinson's disease and relationship to vitamin B level. J. Mov. Disord. 2009, 2, 33-36. [CrossRef] [PubMed]
21. Yuan, R.Y.; Sheu, J.J.; Yu, J.M.; Hu, C.J.; Tseng, I.J.; Ho, C.S.; Yeh, C.Y.; Hung, Y.L.; Chiang, T.R. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients. J. Neurol. Sci. 2009, 287, 64-68. [CrossRef] [PubMed]
22. Białecka, M.; Kurzawski, M.; Roszmann, A.; Robowski, P.; Sitek, E.J.; Honczarenko, K.; Gorzkowska, A.; Budrewicz, S.; Mak, M.; Jarosz, M.; et al. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease. Pharmacogenet Genomics 2012, 22, 716-724. [CrossRef] [PubMed]
23. Song, I.U.; Kim, J.S.; Park, I.S.; Kim, Y.D.; Cho, H.J.; Chung, S.W.; Lee, K.S. Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD). Arch. Gerontol. Geriatr. 2013, 57, 288-291. [CrossRef] [PubMed]
24. Chen, H.; Zhang, S.M.; Schwarzschild, M.A.; Hernán, M.A.; Logroscino, G.; Willett, W.C.; Ascherio, A. Folate intake and risk of Parkinson's disease. Am. J. Epidemiol. 2004, 160, 368-375. [CrossRef] [PubMed]
25. De Lau, L.M.; Koudstaal, P.J.; Witteman, J.C.; Hofman, A.; Breteler, M.M. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology 2006, 67, 315-318. [CrossRef] [PubMed]
26. Murakami, K.; Miyake, Y.; Sasaki, S.; Tanaka, K.; Fukushima, W.; Kiyohara, C.; Tsuboi, Y.; Yamada, T.; Oeda, T.; Miki, T.; et al. Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson's disease: A case-control study in Japan. Br. J. Nutr. 2010, 104, 757-764. [CrossRef] [PubMed]
27. Ehrenshaft, M.; Bilski, P.; Li, M.Y.; Chignell, C.F.; Daub, M. A highly conserved sequence is a novel gene involved in de novo vitamin B6 biosynthesis. Proc. Natl. Acad. Sci. USA 1999, 96, 9374-9378. [CrossRef] [PubMed]
28. Stocker, P.; Lesgards, J.F.; Vidal, N.; Chalier, F.; Prost, M. ESR study of a biological assay on whole blood: Antioxidant efficiency of various vitamins. Biochim. Biophys. Acta 2003, 1621, 1-8. [CrossRef]
29. Cabrini, L.; Bergami, R.; Fiorentini, D.; Marchetti, M.; Landi, L.; Tolomelli, B. Vitamin B6 deficiency affects antioxidant defences in rat liver and heart. Biochem. Mol. Biol. Int. 1998, 46, 689-697. [CrossRef] [PubMed]
30. Mahfouz, M.M.; Kummerow, F.A. Vitamin C or vitamin B6 supplementation prevent the oxidative stress and decrease of prostacyclin generation in homocysteinemic rats. Int. J. Biochem. Cell Biol. 2004, 36, 1919-1932. [CrossRef] [PubMed]
31. Endo, N.; Nishiyama, K.; Otsuka, A.; Kanouchi, H.; Taga, M.; Oka, T. Antioxidant activity of vitamin B6 delays homocysteine-induced atherosclerosis in rats. Br. J. Nutr. 2006, 95, 1088-1093. [CrossRef] [PubMed]
32. Ullegaddi, R.; Powers, H.J.; Gariballa, S.E. B-group vitamin supplementation mitigates oxidative damage after acute ischemic stroke. Clin. Sci. 2004, 107, 477-484. [CrossRef] [PubMed]